23rd week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170157058 | ACID RESISTANT CAPSULE SHELL COMPOSITION, ACID RESISTANT CAPSULE SHELL AND ITS PREPARING PROCESS - The present invention provides an acid resistant capsule shell composition comprising a water-soluble enteric polymer, a water-soluble film forming polymer, a coagulant, and a gelling aid. The water-soluble enteric polymer comprises hydrophobic functional groups and hydrophilic functional groups. The present invention further provides a process for preparing an acid resistant capsule shell comprising: dissolving said acid resistant capsule shell composition in deionized water to form a capsule shell solution; heating then cooling the capsule shell solution to form a capsule shell stock solution; dipping a pin into the capsule shell stock solution then removing the pin to form a film-coated pin; and drying the film-coated pin to form the acid resistant capsule shell. The acid resistant capsule shell has acidic resistance and the process for preparing the acid resistant capsule shell is without organic solvent; hence, the problem of organic solvent residues can be prevented. | 2017-06-08 |
20170157059 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS - A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided. | 2017-06-08 |
20170157060 | ABUSE DETERRENT IMMEDIATE RELEASE COATED RESERVOIR SOLID DOSAGE FORM - An abuse deterrent immediate release coated reservoir solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered. | 2017-06-08 |
20170157061 | Nanoparticulate Meloxicam Formulations - The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm. | 2017-06-08 |
20170157062 | Buprenorphine-Wafer for Drug Substitution Therapy - The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects. | 2017-06-08 |
20170157063 | ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS AND METHODS FOR MAINTAINING HEALTHY SKIN - Compositions and methods for maintaining healthy skin and alleviating skin conditions such as redness, inflammation, irritation and skin aging, as well as for maintaining healthy scalp and hair are disclosed. The oral compositions disclosed comprise antioxidants including lycopene, gallic acid and ascorbic acid. Preferably lycopene has been water-extracted, more preferably under acid conditions. In the method of treatment aspect of the invention, an oral composition containing antioxidant(s) is administered to a person concurrently with a topical treatment for said skin conditions. Preferred topical compositions comprise cyclohexane polyols, such as cyclohexanediol or cyclohexanetriol. | 2017-06-08 |
20170157064 | METHODS FOR THE TREATMENT OF HEPATITIS C - The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs. | 2017-06-08 |
20170157065 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS - Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein. | 2017-06-08 |
20170157066 | PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING A D-AMINO ACID - The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof. | 2017-06-08 |
20170157067 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 2017-06-08 |
20170157068 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN - The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta | 2017-06-08 |
20170157069 | COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS - The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity. | 2017-06-08 |
20170157070 | HYDROXY-SUBSTITUTED AMINO AND AMMONIUM DERIVATIVES AND THEIR MEDICAL USE - The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder. | 2017-06-08 |
20170157071 | REDUCED DOSE INTRAVENOUS ACETAMINOPHEN - Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever. | 2017-06-08 |
20170157072 | NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE - According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in regenerating ascorbate systemically and thus in the therapeutic treatment of chronic obstructive pulmonary disease. | 2017-06-08 |
20170157073 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND USES THEREOF - Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer. | 2017-06-08 |
20170157074 | AGENT FOR IMPROVING NORMAL DEVELOPMENT RATE OF FERTILIZED EGGS - It is intended to provide an in vitro culture medium that allows the in vitro culture of fertilized eggs to progress normally to the blastocyst stage without arresting the development thereof. The normal development rate of a fertilized egg is improved by using 5-aminolevulinic acids represented by the following formula (I) (wherein R | 2017-06-08 |
20170157075 | Edible Compositions and Methods for Promoting Alpha Brain Waves - The present invention provides edible compositions, kits and methods for improving brain function/activity, the composition including at least one alpha brain wave promoting factor including theanine, and at least one neurotransmitter-precursor. | 2017-06-08 |
20170157076 | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS - Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety. | 2017-06-08 |
20170157077 | CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME - Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods. | 2017-06-08 |
20170157078 | MATERNAL CHELATION FOR EMBRYO, FETAL AND INFANT BENEFIT - This invention teaches the use of chelating agents to diagnose and treat metal toxins in a patient. Chelation agents are given to the mother for the benefit of the baby. Metal toxins such as lead, arsenic, mercury, tin, antimony, aluminum and others are known to cause miscarriages, birth defects, maldevelopment of the organs and tissues and maldevelopment of the brain. Chelation treatments of the mother can prevent these problems in the embryo, fetus and infant. Removal of lead and mercury and other toxins allows improved development of the offspring, both during the chelation and after the chelation is discontinued. Determining whether a mother who has just delivered a baby has elevated levels of heavy metals can also be used to identify the elevated metals of the mother as a possible cause of birth defects. | 2017-06-08 |
20170157079 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS - Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations. | 2017-06-08 |
20170157080 | Methods and compositions for the treatment of diverticulosis - The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis. | 2017-06-08 |
20170157081 | SILAGE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Silage compositions are described herein, as well as methods for their preparation and use. A silage composition may include a fatty acid component comprising at least about 70% saturated fatty acid by weight and a fermented component. The fatty acid component may be present in the silage composition in an amount of at least about 10% by weight of the silage composition. | 2017-06-08 |
20170157082 | Extended Duration Local Anesthetic Formulation - An extended duration anesthetic includes a short duration local anesthetic in a dilute solution and a long duration local anesthetic. The long duration local anesthetic is maintained in a powdered form until the time of administration. Premeasured quantities of the dilute solution and powdered long duration local anesthetic in a kit allow for quick preparation of a solution with desired concentrations of both short duration local anesthetic and long duration local anesthetic at the time of administration. | 2017-06-08 |
20170157083 | CONCENTRATED FELBAMATE FORMULATIONS FOR PARENTERAL ADMINISTRATION - Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved a high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size form about 100 nm to about 5 microns, preferably form about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological disease/disorders and/or neurological injury or trauma. | 2017-06-08 |
20170157084 | USE OF COMPOSITION FOR MODULATING ANGIOGENESIS - The present invention relates to a method for modulating angiogenesis in a subject in need thereof, which comprises administering an effective amount of composition comprising excavatolide B and a pharmaceutically acceptable carrier to the subject. | 2017-06-08 |
20170157085 | METHODS AND COMPOSITIONS ADDRESSING DEPRESSED MOOD - A method of treating or preventing depressed mood is describe, such as for treating or preventing postpartum blues or depression or other conditions associated with increased MAO-A levels. The method comprises administering to a subject an antioxidant source at least once between day-1 to day-5 postpartum (or on treatment days 1 to 5 of a non-postpartum regimen); an optional tryptophan composition on the evening of day-3 to day-5, simultaneously or following the antioxidant source; and a tyrosine composition the day after administering the tryptophan composition, for example on day-5. Individuals with depressed mood due to perimenopause, smoking cessation, or due to an alcohol use disorder or withdrawal therefrom may benefit from the treatment | 2017-06-08 |
20170157086 | COMBINATION OF UNSAPONIFIABLE LIPIDS COMBINED WITH POLYPHENOLS AND/OR CATECHINS FOR THE PROTECTION, TREATMENT AND REPAIR OF CARTILAGE IN JOINTS OF HUMANS AND ANIMALS - The present invention relates to a composition for the protection, treatment and repair of cartilage in humans and animal joints. The composition contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. The composition or kit may contain avocado:soybean unsaponifiables (ASU) and green tea. | 2017-06-08 |
20170157087 | 2H-CHROMENE DERIVATIVES AS ANALGESIC AGENTS - The invention relates to the use of the compound of general formula 1 or its spatial isomers | 2017-06-08 |
20170157088 | GLYCOPYRROLATE SALTS - Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed. | 2017-06-08 |
20170157089 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer. | 2017-06-08 |
20170157090 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); | 2017-06-08 |
20170157091 | FORMULATIONS COMPRISING TRIPTAN COMPOUNDS - The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T | 2017-06-08 |
20170157092 | Anti-depression Compounds - This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like. | 2017-06-08 |
20170157093 | Substituted Imidazole Derivatives and Methods of Use Thereof - The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. | 2017-06-08 |
20170157094 | PHARMACEUTICAL FORMULATION COMPRISING LOSARTAN POTASSIUM AND CHLORTHALIDONE - The invention is a pharmaceutical tablet formulation comprising between about 12.5 mg and 100 mg losartan potassium, between about 6.25 mg and about 50 mg chlorthalidone, and sodium bicarbonate in an amount between about 1.0% and about 10.0% by weight. | 2017-06-08 |
20170157095 | ALLISARTAN ISOPROXIL SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION - An allisartan isoproxil solid dispersion, pharmaceutical composition comprising the same and use thereof. The Allisartan Isoproxil solid dispersion consists of Allisartan Isoproxil and a pharmaceutically acceptable carrier material, the carrier material comprising a solubilizing carrier and a surfactant, the mass ratio of Allisartan Isoproxil to the surfactant being 1:0.01˜0.10. | 2017-06-08 |
20170157096 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS - The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I | 2017-06-08 |
20170157097 | METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS - Pharmaceutical compositions of the invention include novel functionalized 1,3-benzenediols having a disease-modifying action in the treatment of hepatic encephalopathy and related conditions. Pharmaceutical compositions of the invention further include novel neuroprotective agents. | 2017-06-08 |
20170157098 | Clopidogrel Hydrogen Sulfate Solid Preparation and Its Preparation Method - To provide a Clopidogrel Hydrogen Sulfate solid preparation, melting granulation process is used, the content of raw material in the granules obtained is high, and the preparation is of good homogeneity, smooth surface, small tablet weight variation and dissolution complying with the clinical medication. When specific crystal form is used, the effect is better. | 2017-06-08 |
20170157099 | PIERICIDIN BACTERIAL INHIBITORS - Described herein are assays for identifying piericidins and piericidin compositions. | 2017-06-08 |
20170157100 | Combinations of Acetylcholinesterase Inhibitors and Muscarinic Agonists and Methods of Use Thereof - A method of treating one or more symptoms associated with underactive bladder in a patient suffering therefrom by administering to the patient a therapeutically effective amount of an acetylcholinesterase inhibitor (AChEI) and an amount of a muscarinic receptor agonist effective to reduce the volume of post void residual in the patient obtained by treatment with the AChEI alone. | 2017-06-08 |
20170157101 | DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALD- EHYDE - Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens. | 2017-06-08 |
20170157102 | USE OF PERHEXILINE - The present invention relates to Perhexiline, or a pharmaceutically acceptable salt thereof, for use in the treatment of a pathology caused by trematodes. | 2017-06-08 |
20170157103 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA USING 3-(4-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE - Provided herein are methods of treating, preventing and/or managing diffuse large B-cell lymphoma (DLBCL), which comprise administering to a patient 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. | 2017-06-08 |
20170157104 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2017-06-08 |
20170157105 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2017-06-08 |
20170157106 | MULTI-PHASE DELIVERY COMPOSITIONS AND PRODUCTS INCORPORATING SUCH COMPOSITIONS - The present disclosure relates to compositions that are useful in the delivery of various materials. In particular, the compositions comprise a suspension wherein an internal phase material is surrounded by an external phase material. The internal phase specifically can be a hydrophilic material, and the external phase specifically can be a hydrophobic material. The materials are combined so that the internal phase is substantially encapsulated by the external phase such that release can be controlled in relation to osmotic pressure differentials. The suspension can be combined with a carrier, and various systems and products can be formed with the suspension and optional carrier, such as oral strips, spray delivery systems, smokeless tobacco products, aerosol delivery devices, cigarettes, and packaging. | 2017-06-08 |
20170157107 | Nicotine-Containing Liquid Formulations and Uses Thereof - Nicotine liquid formulations and their use in therapy, for instance, in nicotine replacement therapy are described. More specifically, the technology relates to liquid nicotine formulations comprising nicotine, one or more diol and/or triol, and a sugar alcohol, which may be used as sprays for administration through the oral cavity, such as the palate. | 2017-06-08 |
20170157108 | LIQUID FORMULATION COMPRISING MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METHOD FOR PREPARING SAME - The present invention relates to a liquid formulation comprising a solubilizer and montelukast or pharmaceutically acceptable salt thereof in a solution state as an active ingredient, and a method for preparing same. The liquid formulation of the present invention allows montelukast or pharmaceutically acceptable salt thereof to be substantially dissolved and present in a solution state, thereby preventing decrease of dissolution over time and increasing its bioavailability. In addition, because the liquid formulation of the present invention shows superior stability, taste and flavor, its medication compliance can be enhanced, and it can be effectively utilized for asthma and allergic rhinitis patients. | 2017-06-08 |
20170157109 | NK3 RECEPTOR ANTAGONIST COMPOUND (NK3RA) FOR USE IN A METHOD FOR THE TREATMENT OF POLYCYSTIC OVARY SYNDROME (PCOS) - A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof. | 2017-06-08 |
20170157110 | METHODS FOR INDUCING INSULIN PRODUCTION AND USES THEREOF - The invention relates to methods of inducing insulin production in delta-cells and/or converting delta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and agents and compositions useful in said methods. | 2017-06-08 |
20170157111 | HIF INHIBITORS AND USE THEREOF - The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders. | 2017-06-08 |
20170157112 | HIF INHIBITORS - The invention provides inhibitors of hypoxia-inducible factors (HIF), and their use in the prevention or inhibition of diseases characterised by abnormal HIF activity or levels, such as tumour progression, and the treatment of cancer. The invention encompasses pharmaceutical compositions with a mechanism of action for blocking elevated HIF activity in diseases, such as cancer. | 2017-06-08 |
20170157113 | 4-(8-METHOXY-1-((1-METHOXYPROPAN-2-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YL)-1 H-IMIDAZO[4,5-C]QUINOLIN-7-YL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN INHIBITOR - Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy. | 2017-06-08 |
20170157117 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS - The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates. | 2017-06-08 |
20170157118 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein: ring A, R | 2017-06-08 |
20170157119 | SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME - Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form. | 2017-06-08 |
20170157120 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. | 2017-06-08 |
20170157121 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS - The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain. | 2017-06-08 |
20170157122 | FUNGICIDAL AGENT - The invention relates to a novel fungicidal agent in the form of a salt associate having the structural formula shown. The agent can be used for treating diseases caused by fungi, and also for preventing fungal damage to various materials and agricultural products. The present fungicidal agent is an associate of 5-[3,5-dichloro-2-hydroxy benzylidene)amino]-4-hydroxy-1H-pyrimidine-2-on with 1,2,3,4,5-pentahydroxy-6-methylaminohexane and has the formula (I). | 2017-06-08 |
20170157123 | CYCLING THERAPY USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE - Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen. | 2017-06-08 |
20170157124 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - The invention provides combinations comprising a) compound of formula I: | 2017-06-08 |
20170157125 | METHOD OF TREATING HYPERTENSION - Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of anagrelide or derivative thereof. The compositions include an effective amount of anagrelide or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension. | 2017-06-08 |
20170157126 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER - Disclosed are methods of treating cancer, which include administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof. | 2017-06-08 |
20170157127 | METHODS OF FACILITATING CELL SURVIVAL USING NEUROTROPHIN MIMETICS - Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75 | 2017-06-08 |
20170157129 | LOW DOSE PHARMACEUTICAL COMPOSITION - Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-1,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound A) in the range of 2.5 mg to 60 mg. Present invention also relates to a method of treating inflammatory bowel disease in a mammal by administrating said low dose pharmaceutical composition. Further, present invention relates to a use of the compound A for the preparation of low dose pharmaceutical composition for the treatment of inflammatory bowel disease in a mammal. | 2017-06-08 |
20170157130 | TREATMENT OF MYELODYSPLASTIC SYNDROME - The present invention relates to the use of Volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (MDS). | 2017-06-08 |
20170157131 | ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT - The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect. The antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof. The present invention also provides a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; a method for inhibiting the growth of a tumor comprising the step of administering to a patient the aforementioned antitumor effect potentiator and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent. | 2017-06-08 |
20170157132 | METHODS OF TREATMENT OF MALIGNANCIES - Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation. | 2017-06-08 |
20170157133 | NOVEL PYRIDAZONES AND TRIAZINONES FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION - The invention provides novel compounds having the general formula: | 2017-06-08 |
20170157134 | COMBINATION THERAPY - A pharmaceutical combination comprising (a) a compound of formula (I), | 2017-06-08 |
20170157135 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS - The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention. | 2017-06-08 |
20170157136 | NOVEL COMPOUNDS - The invention is directed to methods of treatment using compounds of formula (I): | 2017-06-08 |
20170157137 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS - The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R | 2017-06-08 |
20170157138 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE - Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans. | 2017-06-08 |
20170157139 | MUSCARINIC M1 RECEPTOR AGONISTS - This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R | 2017-06-08 |
20170157140 | Methods Of Improving The Pharmacokinetics Of Doxepin - Methods of improving the pharmacokinetics of doxepin in a patient. | 2017-06-08 |
20170157141 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A method of treating leukemia in a mammal by administering a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the Formula (1) wherein R | 2017-06-08 |
20170157143 | NORPREGNANE DERIVATIVES FOR THE RISK REDUCTION OF BREAST CANCER - In one embodiment, the application discloses a method for the prophylaxis or the treatment of a pre-cancerous lesion, including atypical intraductal breast hyperplasia, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising compound of the formula I. | 2017-06-08 |
20170157144 | PREPARATION METHOD FOR ANTITHYROID OINTMENT FOR EXTERNAL APPLICATION - A preparation method for an antithyroid ointment for external application is provided. The ointment includes the following components by mass percentage: 0.01-10% gluco corticoid, 1-15% antithyroid drug, 0.1-30% percutaneous penetration enhancer, 10-30% oleaginous base and 4-40% water-soluble base. The method includes: mixing the glucocorticoid and a drug carrier material so as to evenly disperse the glucocorticoids on the drug carrier material to obtain a glucocorticoid component; placing and evenly mixing an antithyroid drug and other ingredients in distilled water, and heating to 80° C. and evenly mixing to obtain a water phase; melting an oleaginous base and a percutaneous penetration enhancer at 80° C. and evenly mixing to obtain an oil phase; maintaining at 80° C. and pouring the oil phase into the water phase, and evenly stirring; adding the glucocorticoid component when the temperature drops to 40° C.; and evenly and sufficiently stirring until cooled to obtain an ointment. | 2017-06-08 |
20170157145 | SUBSTANCE INDUCING EXPRESSION OF PARKIN POLYPEPTIDE AND USE THEREOF - A method of inducing Parkin expression; inhibiting oxidative stress; and inhibiting cell death of cells by administering deferasirox, hydrocortisone, ketorolac, dexamethasone, and prednisone, a pharmaceutically acceptable salt, stereoisomer, derivative, or solvate thereof to the cell, optionally in a subject, as well as a method of preventing or treating neurodegenerative disease in the subject. | 2017-06-08 |
20170157146 | CO-MICRONISATION PRODUCT COMPRISING ULIPRISTAL ACETATE - The subject of the present invention is a co-micronization product comprising an active ingredient selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and a pharmaceutically acceptable solid surfactant. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof. | 2017-06-08 |
20170157147 | GLUCOCORTICOID-LOADED NANOPARTICLES FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTION AND NEOVASCULARIZATION - Particles encapsulating a glucocorticoid such as dexamethasone sodium phosphate (DSP) into a matrix such as biodegradable poly(lactic-coglycolic acid) (PLGA) which is densely coated with hydrophilic polymer such as PEG or PLURONIC® F127, exhibit sustained release of DSP for up to 7 days in vitro. These nanoparticles can be used to prevent corneal graft rejection or corneal neovascularization. | 2017-06-08 |
20170157148 | TREATMENT OF PROSTATE CANCER - Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. The present invention provides therapies and therapeutic regimens for the treatment of prostate cancer. | 2017-06-08 |
20170157149 | COMPOSITIONS AND METHODS FOR DISEASE TREATMENT USING NANOPARTICLE DELIVERED COMPOUNDS - Provided herein are compositions and methods for the treatment of diseases, such as hyperproliferative diseases, employing compounds formulated for pharmaceutical and research use via nanoparticles. | 2017-06-08 |
20170157150 | ORAL DOSAGE FORM COMPRISING TRI-SUBSTITUTED GLYCEROL COMPOUNDS - The present invention relates to pharmaceutical solid dosage forms for oral administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases. | 2017-06-08 |
20170157151 | Broad Spectrum Antiviral and Methods of Use - A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided. | 2017-06-08 |
20170157152 | OSTEOCLAST INHIBITORS FOR JOINT CONDITIONS - Oral dosage forms of osteoclast inhibitors, such as neridronic acid and zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as joint conditions. | 2017-06-08 |
20170157153 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING COMPLEX REGIONAL PAIN SYNDROME - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome. | 2017-06-08 |
20170157154 | CELL MOBILIZATION AGENT CONTAINING LYSOPHOSPHOLIPID WITH RETINOIC ACID INTRODUCED - The invention provides a cell mobilizing agent capable of efficiently and continuously accumulating cells involved in tissue repair. In particular, the cell mobilizing agent contains a lysophospholipid introduced with retinoic acid represented by the formula (1) and/or the formula (2) or a physiologically acceptable salt thereof as an active ingredient: | 2017-06-08 |
20170157155 | METHOD OF TREATMENT OF NASOPHARYNGEAL CANCER - The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patient's nasopharyngeal cancer tumor sample using a “NFkB p65 IHC assay. The invention also provides a method of determining whether to treat a patient with the compound of formula (/) based on the level of NFkB p65 in the patient's nasopharyngeal cancer tumor sample. | 2017-06-08 |
20170157156 | TRADITIONAL CHINESE MEDICINE COMPOSITION, AND PREPARATION AND APPLICATION THEREOF - A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity. | 2017-06-08 |
20170157157 | METHOD FOR IMPROVING VENTILATORY EFFICIENCY - A method for improving ventilatory efficiency, comprising the administration of a pentose is disclosed. The most preferred pentose is D-ribose, to be administered in a dosage of from two to ten grams, one to four times daily for at least a week, but most preferably long term. | 2017-06-08 |
20170157158 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME II - The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | 2017-06-08 |
20170157159 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME I - The present invention relates to the use of Volasertib or a salt thereof or the hydrate thereof in combination with Decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | 2017-06-08 |
20170157160 | METHODS AND FORMULATIONS FOR TREATING SIALIC ACID DEFICIENCIES - The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations. | 2017-06-08 |
20170157161 | Anti-Cancer Therapies - Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed. | 2017-06-08 |
20170157162 | NUCLEOBASE ANALOGUE DERIVATIVES AND THEIR APPLICATIONS - Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed. | 2017-06-08 |